Literature DB >> 19382128

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

Takeru Shiroiwa1, Yoon-Kyoung Sung, Takashi Fukuda, Hui-Chu Lang, Sang-Cheol Bae, Kiichiro Tsutani.   

Abstract

Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and $50 000-$100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT$ 2.1 million (Taiwan), 23 000 UK pounds (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making. Copyright (c) 2009 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 19382128     DOI: 10.1002/hec.1481

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  183 in total

1.  Cost-effectiveness of chronic kidney disease mass screening test in Japan.

Authors:  Masahide Kondo; Kunihiro Yamagata; Shu-ling Hoshi; Chie Saito; Koichi Asahi; Toshiki Moriyama; Kazuhiko Tsuruya; Hideaki Yoshida; Kunitoshi Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-12-14       Impact factor: 2.801

2.  Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Authors:  Takeru Shiroiwa; Yoshiharu Motoo; Kiichiro Tsutani
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

Review 3.  Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors:  Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

4.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

5.  Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.

Authors:  T Mori; C J Crandall; D A Ganz
Journal:  Osteoporos Int       Date:  2017-02-17       Impact factor: 4.507

6.  Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Authors:  Samuel Herzog; Marian Shanahan; Peter Grimison; Anh Tran; Nicole Wong; Nicholas Lintzeris; John Simes; Martin Stockler; Rachael L Morton
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

7.  Cost-utility analysis of cataract surgery in Japan: a probabilistic Markov modeling study.

Authors:  Yoshimune Hiratsuka; Masakazu Yamada; Yoko Akune; Akira Murakami; Annabelle A Okada; Hidetoshi Yamashita; Yuichi Ohashi; Naoya Yamagishi; Hiroshi Tamura; Shunichi Fukuhara; Tomoyuki Takura
Journal:  Jpn J Ophthalmol       Date:  2013-04-16       Impact factor: 2.447

8.  Cost-effectiveness of a central venous catheter care bundle.

Authors:  Kate A Halton; David Cook; David L Paterson; Nasia Safdar; Nicholas Graves
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

9.  Cost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.

Authors:  Nicholas Graves; Mary Courtney; Helen Edwards; Anne Chang; Anthony Parker; Kathleen Finlayson
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

10.  Cost-effectiveness of a telephone-delivered intervention for physical activity and diet.

Authors:  Nicholas Graves; Adrian G Barnett; Kate A Halton; Jacob L Veerman; Elisabeth Winkler; Neville Owen; Marina M Reeves; Alison Marshall; Elizabeth Eakin
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.